Efficacy of Adoptive Cell Transfer of Tumor-infiltrating Lymphocytes After Lymphopenia Induction for Metastatic MelanomaPilon-Thomas, Shari*,†; Kuhn, Lisa*; Ellwanger, Sabine‡; Janssen, William‡; Royster, Erica§; Marzban, Suroosh§; Kudchadkar, Ragini§; Zager, Jonathan§; Gibney, Geoffrey§; Sondak, Vernon K.*,§; Weber, Jeffrey*,†,§; Mulé, James J.*,†,§; Sarnaik, Amod A.*,§Journal of Immunotherapy: October 2012 - Volume 35 - Issue 8 - p 615–620 doi: 10.1097/CJI.0b013e31826e8f5f Clinical Studies Buy Abstract Author InformationAuthors Article MetricsMetrics A single-institution pilot clinical trial was performed combining nonmyeloablative chemotherapy and the adoptive transfer of tumor-infiltrating lymphocytes with interleukin-2 in patients with metastatic melanoma. Nineteen patients were enrolled with 13 patients (68%) successfully completing treatment. An overall response rate (partial and complete responses) of 26% by intention to treat was achieved with a median follow-up time of 10 months. Of the 13 treated patients, there were 2 complete responses and 3 partial responses (38% response rate among treated patients), along with 4 patients with stable disease ranging from 2+ to 24+months. Three of the 4 patients with stable disease have had disease control without additional therapy, including one at 24+ months. Adoptive therapy with infiltrating lymphocytes is labor intensive but feasible and has a high response rate in treated patients. *Donald A. Adam Comprehensive Melanoma Research Center †Immunology Program ‡Cell Therapies Core Facility §Cutaneous Oncology Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL Reprints: Amod Sarnaik, H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Dr., SRB-4, Tampa, FL 33612. (e-mail: firstname.lastname@example.org). Received July 24, 2012 Accepted August 1, 2012 © 2012 Lippincott Williams & Wilkins, Inc.